Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
April, 2026
April 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  
Wolfgang Miesbach: Beyond Immunosuppression – Two new ways to treat ITP
Wolfgang Miesbach/LinkedIn
Dec 7, 2025, 16:21

Wolfgang Miesbach: Beyond Immunosuppression – Two new ways to treat ITP

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:

“Beyond Immunosuppression: Two new ways to treat ITP. David Kuter gave a great presentation at ASH 2025:

  1. Increase Platelet Production
    The latest TPO receptor agonist, hetrombopag, now in Phase 3 trials, offers a direct pathway to boost platelet synthesis—moving away from suppression toward restoration.
  2. Decrease Platelet Destruction
    A diverse arsenal of targeted therapies can redefineour strategy:
    – Anti-CD38 antibodies (daratumumab, mezagitamab)
    – BAFF/BAFF-R inhibitors
    – FcRn inhibitors (efgartigimod)
    – BTK inhibitors (rilzabrutinib, orelabrutinib)
    – Complement inhibitors + immunomodulatory approaches
    – T-cell engagers and CAR-T therapies

ITP is now recognized as a disorder of both reduced production AND increased destruction—this understanding drives treatment selection toward complete remission, not just disease suppression.”

Wolfgang Miesbach

Find the full coverage of ASH25 in Hemostasis Today.

AHS25 ASH 2025 CAR-T Therapy Daratumumab David Kuter Health Hematology Hemostasis Today Immunosuppression ITP Medicine Mezagitamab Platelet T-cell TPO Wolfgang Miesbach
NewsFeed